 | • レポートコード：GIR201107923 • 出版社/出版日：GlobalInfoResearch / 2020年10月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール • 産業分類：医薬品・医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本書では、耐性緑膿菌感染症治療薬の世界市場を調査対象にし、耐性緑膿菌感染症治療薬の市場概要、メーカー情報、メーカー別販売量・売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（半合成ペニシリン、セファロスポリン、ラクタム系薬剤、その他）、用途別分析（病院、クリニック、在宅医療）、市場予測（2021年～2025年）、販売チャンネル・代理店分析情報などを整理しました。 ・市場概要 ・メーカー情報：ContraFect Corp、Biolytics Pharma、LegoChem Biosciences Inc、Inhibrx LP、AmpliPhi Biosciences Corp、Achaogen Inc、Novartis AG、Melinta Therapeutics Inc、Shionogi & Co Ltd ・メーカー別販売量、売上、市場シェア ・耐性緑膿菌感染症治療薬の地域別市場分析 ・耐性緑膿菌感染症治療薬の北米市場規模2015-2020：アメリカ、カナダ、メキシコ ・耐性緑膿菌感染症治療薬のヨーロッパ市場規模2015-2020：ドイツ、イギリス、フランス、ロシアなど ・耐性緑膿菌感染症治療薬のアジア市場規模2015-2020：日本、中国、韓国、インド、東南アジアなど ・耐性緑膿菌感染症治療薬の南米市場規模2015-2020：ブラジル、アルゼンチンなど ・耐性緑膿菌感染症治療薬の中東・アフリカ市場規模2015-2020：サウジアラビア、トルコ、エジプト、南アフリカなど ・耐性緑膿菌感染症治療薬の種類別市場規模2015-2020：半合成ペニシリン、セファロスポリン、ラクタム系薬剤、その他 ・耐性緑膿菌感染症治療薬の用途別市場規模2015-2020：病院、クリニック、在宅医療 ・耐性緑膿菌感染症治療薬の世界市場予測2021-2025：地域別、種類別、用途別 ・販売チャンネル・代理店分析 ・調査の結果・結論 |
Market Overview
The global Resistant Pseudomonas Aeruginosa Infections Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Resistant Pseudomonas Aeruginosa Infections Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Resistant Pseudomonas Aeruginosa Infections Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Resistant Pseudomonas Aeruginosa Infections Drugs market has been segmented into
Semi-Synthetic Penicillin
Cephalosporin
Lactam Drugs
Others
By Application, Resistant Pseudomonas Aeruginosa Infections Drugs has been segmented into:
Hospital
Clinic
Home Care
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Resistant Pseudomonas Aeruginosa Infections Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Resistant Pseudomonas Aeruginosa Infections Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Resistant Pseudomonas Aeruginosa Infections Drugs market.
The report offers in-depth assessment of the growth and other aspects of the Resistant Pseudomonas Aeruginosa Infections Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Resistant Pseudomonas Aeruginosa Infections Drugs Market Share Analysis
Resistant Pseudomonas Aeruginosa Infections Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Resistant Pseudomonas Aeruginosa Infections Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Resistant Pseudomonas Aeruginosa Infections Drugs sales, revenue and market share for each player covered in this report.
The major players covered in Resistant Pseudomonas Aeruginosa Infections Drugs are:
ContraFect Corp
Biolytics Pharma
LegoChem Biosciences Inc
Inhibrx LP
AmpliPhi Biosciences Corp
Achaogen Inc
Novartis AG
Melinta Therapeutics Inc
Shionogi & Co Ltd
Among other players domestic and global, Resistant Pseudomonas Aeruginosa Infections Drugs market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Resistant Pseudomonas Aeruginosa Infections Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Resistant Pseudomonas Aeruginosa Infections Drugs, with price, sales, revenue and global market share of Resistant Pseudomonas Aeruginosa Infections Drugs in 2018 and 2019.
Chapter 3, the Resistant Pseudomonas Aeruginosa Infections Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Resistant Pseudomonas Aeruginosa Infections Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Resistant Pseudomonas Aeruginosa Infections Drugs market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Resistant Pseudomonas Aeruginosa Infections Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Resistant Pseudomonas Aeruginosa Infections Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Semi-Synthetic Penicillin
1.2.3 Cephalosporin
1.2.4 Lactam Drugs
1.2.5 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Home Care
1.4 Overview of Global Resistant Pseudomonas Aeruginosa Infections Drugs Market
1.4.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 ContraFect Corp
2.1.1 ContraFect Corp Details
2.1.2 ContraFect Corp Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 ContraFect Corp SWOT Analysis
2.1.4 ContraFect Corp Product and Services
2.1.5 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Biolytics Pharma
2.2.1 Biolytics Pharma Details
2.2.2 Biolytics Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Biolytics Pharma SWOT Analysis
2.2.4 Biolytics Pharma Product and Services
2.2.5 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 LegoChem Biosciences Inc
2.3.1 LegoChem Biosciences Inc Details
2.3.2 LegoChem Biosciences Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 LegoChem Biosciences Inc SWOT Analysis
2.3.4 LegoChem Biosciences Inc Product and Services
2.3.5 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Inhibrx LP
2.4.1 Inhibrx LP Details
2.4.2 Inhibrx LP Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Inhibrx LP SWOT Analysis
2.4.4 Inhibrx LP Product and Services
2.4.5 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 AmpliPhi Biosciences Corp
2.5.1 AmpliPhi Biosciences Corp Details
2.5.2 AmpliPhi Biosciences Corp Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 AmpliPhi Biosciences Corp SWOT Analysis
2.5.4 AmpliPhi Biosciences Corp Product and Services
2.5.5 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Achaogen Inc
2.6.1 Achaogen Inc Details
2.6.2 Achaogen Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Achaogen Inc SWOT Analysis
2.6.4 Achaogen Inc Product and Services
2.6.5 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Novartis AG
2.7.1 Novartis AG Details
2.7.2 Novartis AG Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Novartis AG SWOT Analysis
2.7.4 Novartis AG Product and Services
2.7.5 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Melinta Therapeutics Inc
2.8.1 Melinta Therapeutics Inc Details
2.8.2 Melinta Therapeutics Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Melinta Therapeutics Inc SWOT Analysis
2.8.4 Melinta Therapeutics Inc Product and Services
2.8.5 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 Shionogi & Co Ltd
2.9.1 Shionogi & Co Ltd Details
2.9.2 Shionogi & Co Ltd Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Shionogi & Co Ltd SWOT Analysis
2.9.4 Shionogi & Co Ltd Product and Services
2.9.5 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturer Market Share in 2019
3.3.2 Top 6 Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Regions (2015-2020)
4.1.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Market Share by Regions (2015-2020)
4.2 North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
4.3 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
4.5 South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Market Share by Country
5.1.1 North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Country (2015-2020)
5.1.2 North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Market Share by Country (2015-2020)
5.2 United States Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
5.3 Canada Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
5.4 Mexico Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Market Share by Country
6.1.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Country (2015-2020)
6.1.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Market Share by Country (2015-2020)
6.2 Germany Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
6.3 UK Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
6.4 France Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
6.5 Russia Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
6.6 Italy Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Market Share by Regions (2015-2020)
7.2 China Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
7.3 Japan Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
7.4 Korea Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
7.5 India Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
7.7 Australia Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Market Share by Country
8.1.1 South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Country (2015-2020)
8.1.2 South America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Market Share by Country (2015-2020)
8.2 Brazil Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
8.3 Argentina Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
9.3 Turkey Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
9.4 Egypt Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
9.5 South Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Type (2015-2020)
10.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Market Share by Type (2015-2020)
10.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Type (2015-2020)
11 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Segment by Application
11.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2015-2020)
11.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Application (2015-2020)
11.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Application (2015-2020)
12 Market Forecast
12.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Growth Rate (2021-2025)
12.2 Resistant Pseudomonas Aeruginosa Infections Drugs Market Forecast by Regions (2021-2025)
12.2.1 North America Resistant Pseudomonas Aeruginosa Infections Drugs Market Forecast (2021-2025)
12.2.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Market Forecast (2021-2025)
12.2.3 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Market Forecast (2021-2025)
12.2.4 South America Resistant Pseudomonas Aeruginosa Infections Drugs Market Forecast (2021-2025)
12.2.5 Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Market Forecast (2021-2025)
12.3 Resistant Pseudomonas Aeruginosa Infections Drugs Market Forecast by Type (2021-2025)
12.3.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Type (2021-2025)
12.3.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Share Forecast by Type (2021-2025)
12.4 Resistant Pseudomonas Aeruginosa Infections Drugs Market Forecast by Application (2021-2025)
12.4.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Application (2021-2025)
12.4.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Resistant Pseudomonas Aeruginosa Infections Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. ContraFect Corp Basic Information, Manufacturing Base and Competitors
Table 8. ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Major Business
Table 9. ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Total Revenue (USD Million) (2018-2019)
Table 10. ContraFect Corp SWOT Analysis
Table 11. ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
Table 12. ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Biolytics Pharma Basic Information, Manufacturing Base and Competitors
Table 14. Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Major Business
Table 15. Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Total Revenue (USD Million) (2018-2019)
Table 16. Biolytics Pharma SWOT Analysis
Table 17. Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
Table 18. Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. LegoChem Biosciences Inc Basic Information, Manufacturing Base and Competitors
Table 20. LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Major Business
Table 21. LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Total Revenue (USD Million) (2018-2019)
Table 22. LegoChem Biosciences Inc SWOT Analysis
Table 23. LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
Table 24. LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Inhibrx LP Basic Information, Manufacturing Base and Competitors
Table 26. Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Major Business
Table 27. Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Total Revenue (USD Million) (2018-2019)
Table 28. Inhibrx LP SWOT Analysis
Table 29. Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
Table 30. Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. AmpliPhi Biosciences Corp Basic Information, Manufacturing Base and Competitors
Table 32. AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Major Business
Table 33. AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Total Revenue (USD Million) (2018-2019)
Table 34. AmpliPhi Biosciences Corp SWOT Analysis
Table 35. AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
Table 36. AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Achaogen Inc Basic Information, Manufacturing Base and Competitors
Table 38. Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Major Business
Table 39. Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Total Revenue (USD Million) (2018-2019)
Table 40. Achaogen Inc SWOT Analysis
Table 41. Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
Table 42. Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 44. Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Major Business
Table 45. Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Total Revenue (USD Million) (2018-2019)
Table 46. Novartis AG SWOT Analysis
Table 47. Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
Table 48. Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Melinta Therapeutics Inc Basic Information, Manufacturing Base and Competitors
Table 50. Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Major Business
Table 51. Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Total Revenue (USD Million) (2018-2019)
Table 52. Melinta Therapeutics Inc SWOT Analysis
Table 53. Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
Table 54. Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. Shionogi & Co Ltd Basic Information, Manufacturing Base and Competitors
Table 56. Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Major Business
Table 57. Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Total Revenue (USD Million) (2018-2019)
Table 58. Shionogi & Co Ltd SWOT Analysis
Table 59. Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
Table 60. Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 61. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Manufacturer (2018-2019) (K Pcs)
Table 62. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Manufacturer (2018-2019) (USD Million)
Table 63. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Regions (2015-2020) (K Pcs)
Table 64. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Regions (2015-2020)
Table 65. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Regions (2015-2020) (USD Million)
Table 66. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Countries (2015-2020) (K Pcs)
Table 67. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Countries (2015-2020)
Table 68. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Countries (2015-2020) (USD Million)
Table 69. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Countries (2015-2020)
Table 70. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Countries (2015-2020) (K Pcs)
Table 71. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Countries (2015-2020)
Table 72. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Countries (2015-2020) (USD Million)
Table 73. Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Regions (2015-2020) (K Pcs)
Table 74. Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Regions (2015-2020)
Table 75. Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Regions (2015-2020) (USD Million)
Table 76. South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Countries (2015-2020) (K Pcs)
Table 77. South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Countries (2015-2020)
Table 78. South America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Countries (2015-2020) (USD Million)
Table 79. South America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Countries (2015-2020)
Table 80. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Countries (2015-2020) (K Pcs)
Table 81. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Countries (2015-2020)
Table 82. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Countries (2015-2020) (USD Million)
Table 83. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Countries (2015-2020)
Table 84. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2015-2020) (K Pcs)
Table 85. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Type (2015-2020)
Table 86. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2015-2020) (USD Million)
Table 87. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Type (2015-2020)
Table 88. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2015-2020) (K Pcs)
Table 89. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Application (2015-2020)
Table 90. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Regions (2021-2025) (K Pcs)
Table 91. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Share Forecast by Regions (2021-2025)
Table 92. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Type (2021-2025) (K Pcs)
Table 93. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Share Forecast by Type (2021-2025)
Table 94. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Application (2021-2025)
Table 95. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Share Forecast by Application (2021-2025)
Table 96. Direct Channel Pros & Cons
Table 97. Indirect Channel Pros & Cons
Table 98. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Resistant Pseudomonas Aeruginosa Infections Drugs Picture
Figure 2. Global Sales Market Share of Resistant Pseudomonas Aeruginosa Infections Drugs by Type in 2019
Figure 3. Semi-Synthetic Penicillin Picture
Figure 4. Cephalosporin Picture
Figure 5. Lactam Drugs Picture
Figure 6. Others Picture
Figure 7. Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application in 2018
Figure 8. Hospital Picture
Figure 9. Clinic Picture
Figure 10. Home Care Picture
Figure 11. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Status and Outlook (2015-2025) (USD Million)
Figure 12. United States Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Canada Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 14. Mexico Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 15. Germany Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 16. France Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 17. UK Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Russia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Italy Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 20. China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Japan Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Korea Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 23. India Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Australia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 26. Brazil Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Egypt Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Saudi Arabia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 29. South Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Turkey Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 31. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Manufacturer in 2019
Figure 32. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Manufacturer in 2019
Figure 33. Top 3 Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturer (Revenue) Market Share in 2019
Figure 34. Top 6 Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturer (Revenue) Market Share in 2019
Figure 35. Key Manufacturer Market Share Trend
Figure 36. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 37. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 38. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Regions (2015-2020)
Figure 39. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Regions in 2018
Figure 40. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
Figure 41. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
Figure 42. Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
Figure 43. South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
Figure 44. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020)
Figure 45. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 46. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Countries (2015-2020)
Figure 47. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Countries in 2018
Figure 48. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 49. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Countries in 2018
Figure 50. United States Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 51. Canada Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 52. Mexico Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 53. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 54. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Countries (2015-2020)
Figure 55. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Countries in 2019
Figure 56. Germany Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 57. UK Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 58. France Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 59. Russia Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 60. Italy Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 61. Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 62. Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Regions 2019
Figure 63. Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Regions 2019
Figure 64. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 65. Japan Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 66. Korea Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 67. India Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 68. Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 69. South America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 70. South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Countries in 2019
Figure 71. South America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Countries in 2019
Figure 72. Brazil Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 73. Argentina Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 74. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 75. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Countries in 2019
Figure 76. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Countries (2015-2020)
Figure 77. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Countries in 2019
Figure 78. Saudi Arabia Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 79. Egypt Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 80. Turkey Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 81. South Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 82. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2025) (K Pcs)
Figure 83. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2021-2025) (USD Million)
Figure 84. North America Sales Resistant Pseudomonas Aeruginosa Infections Drugs Market Forecast (2021-2025) (K Pcs)
Figure 85. Europe Sales Resistant Pseudomonas Aeruginosa Infections Drugs Market Forecast (2021-2025) (K Pcs)
Figure 86. Asia-Pacific Sales Resistant Pseudomonas Aeruginosa Infections Drugs Market Forecast (2021-2025) (K Pcs)
Figure 87. South America Sales Resistant Pseudomonas Aeruginosa Infections Drugs Market Forecast (2021-2025) (K Pcs)
Figure 88. Middle East & Africa Sales Resistant Pseudomonas Aeruginosa Infections Drugs Market Forecast (2021-2025) (K Pcs)
Figure 89. Sales Channel: Direct Channel vs Indirect Channel
緑膿菌性肺炎治療薬の世界市場 2020年 Market Overview The global Pseudomonas Aeruginosa Pneumonia Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Pseudom…- バンコマイシン耐性腸球菌フェシウム治療薬の世界市場 2020年 Market Overview The global Drugs for Vancomycin-Resistant Enterococcus Faecium market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 201…
- エクセナチド薬の世界市場 2020年 Market Overview The global Exenatide Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Exenatide Drugs market report…
- テデュグルチド薬の世界市場 2020年 Market Overview The global Teduglutide Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Teduglutide Drugs market re…
- 髄膜炎菌感染症ワクチンの世界市場 2020年 Market Overview The global Meningococcal Infections Vaccine market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Meningococca…